You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

bosutinib

( boe-SUE-ti-nib )
Funding:
Exceptional Access Program
  • bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Other Name(s): Bosulif®
Appearance: tablet in various strengths and colours

You might also be interested in